Clinical trials: Agitation
RLS
An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
The primary objective of the trial is to evaluate the efficacy of HORIZANT 300 mg and 600 mg, compared to placebo, at 12 weeks of treatment, for the treatment of Restless Legs Syndrome (RLS) in adolescents (13 to 17 years of age)…
- Trial name
- RLS (NCT02560766)
- Testing
- HORIZANT 300 mg, HORIZANT 600 mg
- Where
- 12 sites in United States
- Volunteers
- 132 people
- Sponsor
- XenoPort, Inc.
Haemodialysis-induced Symptom
Sleep Quality and Related Factors in Hemodialysis Patients
Sleep quality is an important predictor of healthy status,quality of life and life span. Sleeping problems affect 50%~80% in hemodialysis patients.
- Trial name
- NCT01327560
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Taipei Medical University WanFang Hospital
Restless Legs Syndrome
Treatment of Restless Legs Syndrome With the Hypocretin Antagonist Suvorexant
Suvorexant improves sleep latency and wake after sleep onset in patients with primary insomnia, and is FDA approved for this condition. However, no data exist on its effects in RLS, so far.
- Trial name
- NCT03755310
- Testing
- Suvorexant
- Where
- Spain
- Volunteers
- 43 people
- Sponsor
- Diego García-Borreguero, MD, PhD
Agitation, Excited Delirium
Stress Biomarkers Among Patients Undergoing Treatment for Excited Delirium and Severe Pain in the Emergency Department
The purpose of this project is to determine the levels of stress biomarkers associated with severe pain, agitation from intoxication or psychosis, and excited delirium at various levels of the disease in order to compare them to…
- Conditions
- Agitation, Excited Delirium, Pain
- Trial name
- Agitation (NCT01747824)
- Where
- United States
- Volunteers
- 1,322 people
- Sponsor
- Hennepin Healthcare Research Institute
Restless Legs Syndrome
Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine
This double-blind study will evaluate the pharmacokinetics of a single dose of morphine or gabapentin derived from gabapentin enacarbil (GEn) after administration of morphine and GEn alone and in combination as well as the…
- Trial name
- NCT01476124
- Testing
- GEn 600 mg, Morphine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- XenoPort, Inc.
Specified Sedative, Hypnotic
Dyphenhidramine Effect on Prevention of Sevoflurane Induced Post Anesthesia Agitation in Pediatric
The purpose of this study is to investigate the effect of diphenhydramine on the prevention of sevoflurane induced emergence delirium/ agitation in pediatrics.
- Trial name
- NCT02463929
- Testing
- Diphenhydramine, normal saline, Ketamine
- Volunteers
- 50 people
- Sponsor
- Universitas Diponegoro
Alzheimer's Disease
CALM-AD
Primary Aim To determine whether; Donepezil is significantly better than placebo in the management of agitation in Alzheimer's Disease that has not responded to, or is inappropriate for a standardised brief psychosocial treatment…
- Trial name
- NCT00142324
- Testing
- Donepezil
- Where
- 8 sites in United Kingdom
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Institute of Psychiatry, London
Renal Failure Chronic, Restless Legs Syndrome
Massage, Oxidative and Antioxidant Enzymes in Hemodialysis Patients With Restless Legs Syndrome(RLS)
This study; It will be done to evaluate the presence of oxidative stress and its effects on lipid peroxidation products and antioxidant parameters after massage application and the possible effects of the appropriate massage…
- Trial name
- RLS (NCT05787080)
- Testing
- Massage
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Baskent University
Restless Legs Syndrome
Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)
This is a multi-center, open-label extension trial conducted at the same European sites that participated in trial SP 709 (NCT00243217).
- Trial name
- NCT00498186
- Testing
- Rotigotine
- Where
- 24 sites in Austria, Germany and 1 more
- Volunteers
- 295 people
- Sponsor
- UCB Pharma
Agitation in the Elderly
A Study of BNC210 in Elderly Patients With Agitation
This is a Phase II randomised, double-blind, placebo-controlled study assessing the effects of BNC210 on agitation in hospitalised elderly patients as measured by the Pittsburgh Agitation Scale (PAS).
- Trial name
- NCT03548194
- Testing
- BNC210
- Where
- 5 sites in Australia
- Volunteers
- 38 people
- Sponsor
- Bionomics Limited
Alzheimer Disease, Anxiety
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
This is an open label, eight week, clinical trial of a proprietary high CBD/low THC sublingual solution for the treatment of clinically significant anxiety and agitation in individuals with mild cognitive impairment (MCI) or mild…
- Conditions
- Alzheimer Disease, Anxiety, Agitation,Psychomotor, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
- Trial name
- CBD (NCT04075435)
- Testing
- high CBD/low THC sublingual solution
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mclean Hospital
Dementia, Aggression
Study of Electroconvulsive Therapy (ECT) Treatment for Agitation and Aggression in Dementia
Agitation/aggression is one of the most common and serious behavioral complications of dementia. If the behavior is refractory to standard care (behavior approaches and off label use of psychotropic medications), other evidence…
- Conditions
- Dementia, Aggression, Agitation
- Trial name
- NCT01856010
- Testing
- ECT treatment, Standard Care (Non-ECT group)
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pine Rest Christian Mental Health Services
Schizophrenia
Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia
The purpose of this study is to examine the clinical therapeutic dose in Japanese agitated patients with schizophrenia.
- Trial name
- NCT00485810
- Testing
- Olanzapine Hydrochloride
- Where
- Japan
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company